| Title |
Antiplatelet agents for chronic kidney disease
|
|---|---|
| Published by |
John Wiley & Sons, Ltd, February 2013
|
| DOI | 10.1002/14651858.cd008834.pub2 |
| Pubmed ID | |
| Authors |
Palmer, Suetonia C, Di Micco, Lucia, Razavian, Mona, Craig, Jonathan C, Perkovic, Vlado, Pellegrini, Fabio, Jardine, Meg J, Webster, Angela C, Zoungas, Sophia, Strippoli, Giovanni FM |
| Abstract |
Antiplatelet agents are widely used to prevent cardiovascular events. The risks and benefits of antiplatelet treatment may be different in people with chronic kidney disease (CKD) for whom occlusive atherosclerotic events are less prevalent, and bleeding hazards might be increased. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 43% |
| Japan | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | 2% |
| Russia | 1 | 2% |
| France | 1 | 2% |
| Unknown | 45 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 13% |
| Other | 5 | 10% |
| Student > Postgraduate | 4 | 8% |
| Professor | 3 | 6% |
| Student > Master | 3 | 6% |
| Other | 7 | 15% |
| Unknown | 20 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 22 | 46% |